Updates are available Correction dated 2020-04-02
Click to view Correction: https://doi.org/10.1007/s40259-020-00424-z
-
Authors
Patel, Ami https://orcid.org/0000-0002-2104-9984
Bah, Mamadou A. https://orcid.org/0000-0002-3238-1085
Weiner, David B.
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1163327, OPP1201239)
National Institutes of Health (R01AI141236, U19 AI142777)
- License Information
-
More Information
Article History
First Online: 10 March 2020
Change Date: 2 April 2020
Change Type: Correction
Change Details: The article In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies, written by Ami Patel, Mamadou A. Bah and David B.
Compliance with ethical standards
:
: The authors are grateful for funding from The Bill and Melinda Gates Foundation (OPP1163327 and OPP1201239 award to David B. Weiner) and National Institutes of Health (R01 AI141236 award to David B. Weiner and U19 AI142777 subaward to Ami Patel). The research described in this manuscript was funded by The Bill and Melinda Gates Foundation (OPP1163327 and OPP1201239 award to David B. Weiner).
: M. B. declares no competing interests. A. P. is listed as an inventor on patents related to DMAbs. D. B. W. has received grant funding, participates in industry collaborations, has received speaking honoraria, and has received fees for consulting, including serving on scientific review committees and board service. Remuneration received by D. B. W. includes direct payments or stock or stock options, and, in the interest of disclosure, he notes potential conflicts associated with this work with Inovio and possibly others. In addition, he has patents on DMAbs and DNA vaccine delivery.
